Genetically modified T cells for treating relapsed or refractory acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase I/II trial evaluates the safety, feasibility, and efficacy of MB-dNPM1-TCR.1, a treatment involving autologous T cells that are genetically modified to target specific peptides associated with mutated Nucleophosmin in patients with relapsed or refractory acute myeloid leukemia (AML). The trial consists of a dose escalation phase to determine the maximum tolerated dose, followed by an efficacy evaluation phase using a Simon's minimax design. Patients will undergo leukapheresis, receive lymphodepleting chemotherapy, and then be infused with the modified T cells to target and eliminate malignant myeloid cells.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years
2. Patients must be able to understand and be willing to give signed informed consent
3. Relapsed or refractory acute myeloid leukemia (last disease staging within 4 weeks prior to screening) without standard treatment options defined as:

   * No morphological CR or extramedullary AML after at least two courses of intensive chemotherapy, decitabine or other standard therapy or
   * MRD positive after at least two courses of intensive chemotherapy or other standard therapy and not eligible for allogeneic stem cell transplantation or
   * Relapsed bone marrow or blood disease or extramedullary AML after CR after first line treatment and not eligible to undergo allogeneic stem cell transplantation or
   * Bone marrow, blood, extramedullary AML relapse or non-response or MRD positivity after allogeneic stem cell transplantation and not eligible to receive Donor Lymphocyte Infusion (DLI) according to local standards, relapse or MRD positive after DLI.
4. Positive for HLA-A\*02:01 according to genotyping results.
5. AML has NPM1 mutation which is recognized by dNPM1-TCR.1 and for which a specific Q-PCR is available for disease monitoring.
6. Number of circulating WBC above 1x109/L with less than 50% leukemic blasts and 0.03 x 109 CD8+ T cells/L.
7. Life expectancy of at least 3 months.
8. ECOG performance status 0-3.
9. Negative pregnancy test in women of childbearing potential.
10. For fertile men and women, agreement to use highly effective contraceptive methods during the trial.

Exclusion Criteria:

1. Pregnant or breast feeding women.
2. Active infection with HIV-1, HIV-2, HBV, HCV, HTLV-I, HTLV-II, SARS-CoV-2 or Treponema Pallidum.
3. Any clinically significant, advanced or unstable disease or inadequate main organ function that may put the patient at increased risk for severe complications of trial participation at the discretion of the investigator.
4. Use of systemic immune suppression including, but not limited to:

   immunosuppressive agents such as cyclosporine or corticosteroids (at an equivalent dose of 0.5 mg prednisone/kg body weight per day, or higher). Inhaled steroid and physiological replacement for adrenal insufficiency are allowed.
5. Unwillingness or inability to comply with procedures required in this clinical trial protocol.
6. Uncontrolled life-threatening infections or uncontrolled disseminated intravascular coagulation; however, if these problems resolve, the start of treatment can be initiated on a delayed schedule.
7. Subjects currently on any other IMP (including within the last 30 days before start of treatment).
8. Current use of high dose immunosuppression for immune disorders interfering with T cell function (on discretion of the investigator).
9. Known hypersensitivity against any drug of the mandatory trial procedures.
10. Serum creatinine ≥ 2.0 × ULN or eGFR \< 30 mL/min calculated according to the modified MDRD formula.
11. BMI ≥40
12. Has received vaccination with live vaccines 6 weeks prior to treatment
13. Major surgery less than 30 days before start of treatment.
14. Committal to an institution on judicial or official order.

Where it's running

• Leiden University Medical Center
  Leiden, Netherlands Recruiting

Study contacts

• Principal investigator: C.J.M. Halkes, Dr — Leiden University Medical Center
• Study coordinator: Jörg Liebmann
• Email: clinicaltrials.gov@miltenyi.com
• Phone: +49151-2034-4392

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• Orca-T after reduced-intensity or nonmyeloablative conditioning for adults with AML or MDS

  This trial will test whether Orca-T, a donor-derived stem cell and T-cell therapy, is safe and helps adults with acute myeloid leukemia or myelodysplastic syndrome who are receiving reduced-intensity or nonmyeloablative allogeneic stem cell transplants.

  Recruiting at 6 sites Phase 2 Orca Biosystems, Inc. · Los Angeles, California and 5 other locations · NCT07216443

• Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia

  This study is collecting health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia to better understand these conditions and improve patient care.

  Recruiting Groupe Francophone des Myelodysplasies · Rouen · NCT06956755

• Bleximenib added to venetoclax and azacitidine for newly diagnosed NPM1- or KMT2A-mutated AML

  This trial will test whether adding bleximenib to venetoclax plus azacitidine helps people with newly diagnosed AML that has NPM1 or KMT2A mutations who cannot have intensive chemotherapy.

  Recruiting at 270 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 269 other locations · NCT06852222

• Genetic analysis in women with metastatic ovarian cancer during PARP inhibitor treatment

  This study is testing how PARP inhibitor treatment affects the genes and blood cells of women with metastatic ovarian cancer to see if it leads to any serious side effects.

  Recruiting European Institute of Oncology · Milan · NCT06785077

• Combining Venetoclax with Intensive Therapy for Acute Myeloid Leukemia Patients

  This study is testing if adding a drug called Venetoclax to standard chemotherapy can help newly diagnosed acute myeloid leukemia patients who aren't responding well to their initial treatment.

  Recruiting Affiliated Hospital of Nantong University · Nantong, Jiangsu · NCT06643962

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.